Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan versus bosentan in neonates with persistent pulmonary hypertension receiving sildenafil
IRCT20160120026115N9Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in persistent pulmonary hypertension of the newborn (PPHN) comparing Bosentan + sildenafil with Macitentan + sildenafil (2 arms). Primary endpoint: Response to treatment of persistent pulmonary hypertension of the newborn. Started Aug 2021; status: completed.
02
Drugs
macitentanbosentansildenafil
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on IRCT20160120026115N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160120026115N9.